Previous close | 220.58 |
Open | 222.75 |
Bid | 90.18 x 1200 |
Ask | 260.00 x 900 |
Day's range | 220.23 - 226.43 |
52-week range | 203.37 - 460.21 |
Volume | |
Avg. volume | 549,348 |
Market cap | 11.498B |
Beta (5Y monthly) | 1.27 |
PE ratio (TTM) | 27.58 |
EPS (TTM) | 8.20 |
Earnings date | 02 Aug 2022 - 08 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 327.64 |
WILMINGTON, Mass. & GHENT, Belgium, June 23, 2022--Charles River and Ziphius Vaccines collaborate to deliver early-stage clinical supply of plasmid DNA for saRNA-based vaccine program.
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.